A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

被引：0

作者：

Nath, Karthik ^{[1
]}

Shekarkhand, Tala ^{[2
]}

Salcedo, Meghan ^{[2
]}

Derkach, Andriy ^{[3
]}

Rueda, Siobhan ^{[4
]}

Chansakul, Aisara ^{[5
]}

Hulcrantz, Malin ^{[2
]}

Korde, Neha ^{[2
]}

Shah, Urvi A. ^{[2
]}

Tan, Carlyn ^{[2
]}

Chung, David J. ^{[1
,6
]}

Lahoud, Oscar B. ^{[6
]}

Hassoun, Hani ^{[2
]}

Lesokhin, Alexander M. ^{[1
,2
]}

Landau, Heather J. ^{[6
]}

Shah, Gunjan ^{[1
,6
]}

Scordo, Michael ^{[1
,6
]}

Giralt, Sergio A. ^{[1
,6
]}

Usmani, Saad Z. ^{[1
,2
]}

Roshal, Mikhail ^{[7
]}

Landgren, Ola ^{[8
]}

Mailankody, Sham ^{[1
,2
,9
,10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidmiol, New York, NY USA

[4] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

[5] Weill Cornell Med Coll, Emergency Dept, Div Emergency Med, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA

[9] Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10065 USA

[10] Mem Sloan Kettering Canc Ctr, Cellular Therapeut Serv, 1275 York Ave, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 14期

关键词：

OUTCOMES;

D O I：

10.1080/10428194.2022.2131417

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3488 / 3492

页数：5

共 50 条

[21] Minimal residual disease monitoring in multiple myeloma
Davies, FE
Rawstron, RC
Owen, RG
Morgan, GJ
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
[22] Standardisation of minimal residual disease in multiple myeloma
Innao, V.
Allegra, A.
Russo, S.
Gerace, D.
Vaddinelli, D.
Alonci, A.
Allegra, A. G.
Musolino, C.
EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
[23] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
Maiolino, Angelo
Da Costa, Elaine Sobral
Orfao, Alberto
FRONTIERS IN ONCOLOGY, 2023, 13
[24] Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
Rocci, Alberto
Gambella, Manuela
Omede, Paola
Drandi, Daniela
Gay, Francesca
Patriarca, Francesca
Cavallo, Federica
Petrucci, Maria Teresa
Tommaso, Caravita
Benevolo, Giulia
Pescosta, Norbert
Oliva, Stefania
Offidani, Massimo
Montefusco, Vittorio
Liberati, Anna Marina
Falcone, Antonietta Pia
Ballanati, Stelvio
Spadano, Tonino
Guglielmelli, Tommasina
Musto, Pellegrino
Zarnbello, Renato
Di Raimondo, Francesco
Ladetto, Marco
Boccadoro, Mario
Palumbo, Antonio
BLOOD, 2013, 122 (21)
[25] Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
Zamagni, Elena
Tacchetti, Paola
Barbato, Simona
Cavo, Michele
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
[26] Multiple myeloma: Maintenance therapy after autologous stem cell transplantation, depending on minimal residual disease
Solovyev, M. V.
Mendeleeva, L. P.
Pokrovskaya, O. S.
Nareyko, M. V.
Firsova, M. V.
Galtseva, I. V.
Davydova, Yu. O.
Kapranov, N. M.
Kuzmina, L. A.
Gemdzhian, E. G.
Savchenko, V. G.
TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 25 - 31
[27] The clinical significance of the monitoring minimal residual disease for maintanence therapy after autologous stem cells transplantation in patients with multiple myeloma
Shamansky, S.
Fedotova, I.
Novoseltceva, L.
Melkova, C.
Pisarevskaya, O.
Rukavitcin, O.
BONE MARROW TRANSPLANTATION, 2015, 50 : 5597 - 5598
[28] Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy
Kostopoulos, Ioannis V.
Kastritis, Efstathios
Papanota, Aristea-Maria
Micheli, Paraskevi
Malandrakis, Panagiotis
Ntanasis-Stathopoulos, Ioannis
Fotiou, Despina
Kanellias, Nikolaos
Migkou, Magdalini
Eleutherakis-Papaiakovou, Evangelos
Gavriatopoulou, Maria
Tsitsilonis, Ourania
Dimopoulos, Meletios A.
Terpos, Evangelos
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E185 - E186
[29] Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Liu, Jiahui
Yan, Wenqiang
Fan, Huishou
Xu, Jingyu
Li, Lingna
Du, Chenxing
Mao, Xuehan
Yan, Yuting
Xu, Yan
Sui, Weiwei
Deng, Shuhui
Yi, Shuhua
Anderson, Kenneth C.
Qiu, Lugui
Zou, Dehui
An, Gang
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1770 - 1780
[30] Minimal residual disease testing after stem cell transplantation for multiple myeloma
A M Sherrod
P Hari
C A Mosse
R C Walker
R F Cornell
Bone Marrow Transplantation, 2016, 51 : 2 - 12

← 1 2 3 4 5 →